Welcome to our dedicated page for Tarsus Pharmaceuticals SEC filings (Ticker: TARS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tarsus Pharmaceuticals, Inc. filings document operating results, product commercialization, pipeline disclosures, governance matters, and capital-market reporting for a Nasdaq-listed biopharmaceutical company. Form 8-K reports include quarterly and annual financial results, XDEMVY net product sales commentary, corporate presentations, and clinical or commercial business updates involving TP-04 and TP-05.
Proxy and governance filings describe board composition, committee assignments, director elections, executive compensation, auditor ratification, stockholder voting results, and related compensation policies. The filing record also includes material-event disclosures for board appointments, Regulation FD presentations, common-stock voting matters, and formal disclosure of risk, oversight, and governance subjects relevant to Tarsus' commercial-stage pharmaceutical business.
Tarsus Pharmaceuticals director Wendy L. Yarno acquired 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs). Each RSU converted into one share of common stock, reflecting compensation for her service as a non-employee director. The RSUs were granted on June 12, 2025 and vested in full on the one-year anniversary of the grant date, subject to continuous service. Following this RSU settlement, Yarno directly holds 16,654 shares of Tarsus Pharmaceuticals common stock, and the RSU balance from this grant is now fully settled.
Tarsus Pharmaceuticals director Andrew D. Goldberg acquired 2,954 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs). The RSUs were granted on June 12, 2025 for his service as a non-employee director and vested in full one year later.
Following this compensation-related share issuance, Goldberg directly holds 19,654 shares of Tarsus common stock. The filing shows no open-market purchases or sales, only the conversion of previously granted RSUs into common shares.
Tarsus Pharmaceuticals, Inc. filed a Form 144 notifying a proposed sale of 12,500 shares of Common Stock by William J. Link. The shares are identified as from a Stock Option Exercise dated 01/10/2017 and the method of sale is listed as Cash.
The filing also lists a sale of 12,500 shares on 03/16/2026 with proceeds of $859,787.14.
Tarsus Pharmaceuticals reports a Schedule 13G showing Janus Henderson Group plc beneficial ownership of 2,240,963 shares of Common Stock as of 03/31/2026. The filing states this position represents 5.3% of the class and that the Asset Managers exercise shared voting and dispositive power on behalf of managed client accounts.
The filing clarifies the Asset Managers generally exercise investment and voting discretion for Managed Portfolios and disclaim rights to receive dividends or sale proceeds tied to those accounts.
Tarsus Pharmaceuticals, Inc. Schedule 13G/A amendment reports that Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd. and David Kroin each beneficially own 3,600,000 shares of Common Stock, representing 8.46%, as of March 31, 2026.
The filing states the beneficial ownership percentages are calculated using 42,557,492 shares outstanding as of February 17, 2026 per the issuer's 10-K. The filing is a joint statement by the reporting persons and identifies Deep Track Capital, LP as the relevant entity for control relationships.
Prudential Financial, Inc. filed an Amendment No. 20 on Schedule 13G/A reporting beneficial ownership of 1,836,321 shares of Common Stock of Tarsus Pharmaceuticals, Inc. (4.3%) as of 03/31/2026. The filing shows shared voting power of 1,670,648 and shared dispositive power of 1,836,321. The disclosure attributes holdings to subsidiaries, including Jennison Associates LLC: 1,712,124 shares (4.0%), The Prudential Insurance Company of America: 117,972 shares (0.3%), and PGIM Quantitative Solutions LLC: 6,225 shares.
TARSUS PHARMACEUTICALS INC Schedule 13G/A amendment reports that Jennison Associates LLC beneficially owns 1,712,124 shares of common stock, representing 4.0% of the class. The filing lists sole voting power for 1,712,124 shares and shared dispositive power for 1,712,124 shares.
Tarsus Pharmaceuticals reported strong top-line growth but continued losses for the quarter ended March 31, 2026. Total revenue reached $162.1 million, driven by $145.4 million in XDEMVY product sales and $16.7 million of license and collaboration revenue.
Operating expenses rose to $168.2 million, mainly from higher selling, general and administrative and R&D spending. Net loss narrowed to $7.0 million, or $0.16 per share, compared with a $25.1 million loss a year earlier. Cash, cash equivalents and marketable securities totaled over $388 million, and management believes existing capital will fund operations for at least 12 months, though additional financing may still be needed as the company scales commercialization and advances its pipeline.
Tarsus Pharmaceuticals reported strong first quarter 2026 growth driven by XDEMVY. Net product sales were $145.4 million, more than 85% higher than a year earlier, and total revenue reached about $162.1 million including $16.7 million of license and collaboration revenue from a China milestone.
The company reaffirmed full-year 2026 XDEMVY net product sales guidance of $670–700 million and continues to highlight peak sales potential exceeding $2 billion. Operating expenses rose as Tarsus invested heavily in commercialization and R&D, yet net loss narrowed to $7.0 million, or $(0.16) per share.
Cash, cash equivalents and marketable securities totaled $388.7 million as of March 31, 2026, supporting a pipeline that includes Phase 2 programs for ocular rosacea (TP-04) and Lyme disease prevention (TP-05), with topline data from both expected in the first half of 2027.